PPA
MRNA icon

Parametric Portfolio Associates’s Moderna MRNA Stock Holding History

Parametric Portfolio Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$138M Buy
799,388
+82,470
+12% +$13.9M 0.07% 255
2021
Q4 		$182M Sell
716,918
-93,334
-12% -$27.3M 0.09% 194
2021
Q3 		$312M Buy
810,252
+369,004
+84% +$136M 0.18% 97
2021
Q2 		$104M Buy
441,248
+25,332
+6% +$4.53M 0.06% 320
2021
Q1 		$54.5M Buy
415,916
+48,028
+13% +$6.96M 0.03% 546
2020
Q4 		$38.4M Buy
367,888
+48,940
+15% +$4.95M 0.02% 661
2020
Q3 		$22.6M Buy
318,948
+38,824
+14% +$2.71M 0.02% 826
2020
Q2 		$18M Buy
280,124
+75,563
+37% +$4.14M 0.01% 944
2020
Q1 		$6.13M Buy
204,561
+89,418
+78% +$2.06M 0.01% 1579
2019
Q4 		$2.25M Buy
115,143
+16,030
+16% +$284K ﹤0.01% 2616
2019
Q3 		$1.58M Buy
99,113
+65,223
+192% +$963K ﹤0.01% 2788
2019
Q2 		$496K Buy
+33,890
New +$728K ﹤0.01% 3369

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parametric Portfolio Associates's MRNA Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Moderna (MRNA) stake by 12% in Q1 2022, buying an estimated $13.9M and bringing the position to 799,388 shares worth $138M. The position accounts for 0.07% of the portfolio, ranked #255.

Parametric Portfolio Associates first reported a position in MRNA in Q2 2019 and has held it in 12 quarters since. The position peaked at $312M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Parametric Portfolio Associates held 799,388 shares of Moderna worth $138M as of Q1 2022.
  • Parametric Portfolio Associates bought 82,470 Moderna shares in Q1 2022, an estimated $13.9M.
  • Moderna made up 0.07% of Parametric Portfolio Associates's portfolio in Q1 2022, its #255 holding.
  • Parametric Portfolio Associates first reported a position in Moderna in Q2 2019 and has held it in 12 quarters since.
  • Parametric Portfolio Associates's Moderna position peaked at $312M in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.